AIM Historical Income Statement
| AIM Stock | USD 0.20 0.00 0.00% |
Historical analysis of AIM ImmunoTech income statement accounts such as Total Revenue of 172.7 K, Gross Profit of 151.2 K or Other Operating Expenses of 38.8 M can show how well AIM ImmunoTech performed in making a profits. Evaluating AIM ImmunoTech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AIM ImmunoTech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining AIM ImmunoTech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AIM ImmunoTech is a good buy for the upcoming year.
AIM |
About AIM Income Statement Analysis
AIM ImmunoTech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AIM ImmunoTech shareholders. The income statement also shows AIM investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
AIM ImmunoTech Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts AIM ImmunoTech generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AIM ImmunoTech. It is also known as AIM ImmunoTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from AIM ImmunoTech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Interest Income is very stable compared to the past year.
| 2022 | 2024 | 2025 (projected) | Interest Expense | 478K | 549.7K | 281.1K | Research Development | 7.0M | 12.6M | 6.9M |
AIM ImmunoTech income statement Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 706K | 805K | (424K) | 238K | 214.2K | 203.5K | |
| Total Revenue | 163K | 135K | 141K | 202K | 181.8K | 172.7K | |
| Gross Profit | (643K) | (715K) | (19.8M) | 160K | 144K | 151.2K | |
| Other Operating Expenses | 15.2M | 17.2M | 20.1M | 32.1M | 36.9M | 38.8M | |
| Operating Income | (15.2M) | (18.8M) | (19.9M) | (31.9M) | (28.7M) | (27.3M) | |
| Ebit | (13.7M) | (19.1M) | (19.4M) | (31.9M) | (28.7M) | (27.3M) | |
| Ebitda | (13.0M) | (18.3M) | (19.9M) | (31.7M) | (28.5M) | (27.1M) | |
| Cost Of Revenue | 806K | 850K | 19.9M | 42K | 48.3K | 45.9K | |
| Total Operating Expenses | 14.4M | 16.3M | 20.1M | 32.1M | 36.9M | 38.7M | |
| Income Before Tax | (14.4M) | (19.1M) | (19.4M) | (29.0M) | (26.1M) | (24.8M) | |
| Total Other Income Expense Net | 752K | (289K) | 478K | 3.0M | 3.4M | 3.6M | |
| Net Income | (16.3M) | (21.5M) | (21.1M) | (29.0M) | (26.1M) | (24.8M) | |
| Income Tax Expense | 1.3M | 1.9M | 2.4M | 1.6M | 1.9M | 1.3M | |
| Research Development | 5.7M | 7.7M | 7.0M | 10.9M | 12.6M | 6.9M | |
| Interest Expense | 427K | 672K | 67K | 478K | 549.7K | 281.1K | |
| Selling General Administrative | 8.7M | 8.7M | 13.1M | 21.1M | 24.3M | 25.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth 0.19 | Return On Assets | Return On Equity |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.